Subsequently, a combination therapy involving cisplatin and SCD1/FADS2 inhibitors synergistically inhibited OC cell dissemination, presenting a promising chemotherapeutic strategy for managing peritoneal metastases in epithelial ovarian cancer [35]. Here, FADS2 is linked to ovarian carcinoma.